Switch Maintenance Study
Ontology highlight
ABSTRACT: Interventions: CapeOX+Bev ;Capecitabine1000mg/m2 oral administration twice a day Day1-15+Oxaliplatin130mg/m2 120minute DIV+Bevacizumab5.0 mg/kg given on day 1,15
FOLFOX+Bev;Oxaliplatin85mg/m2 120minute DIV+LEVOFOLINATE200mg/m2 120minute DIV+Fluorouracil400mg/m2 rapid DIV+Fluorouracil2400mg/m2 46minute DIV+Bevacizumab DIV5.0 mg/kg Day1,15
TAS-102+Bev;TAS-102 35 mg/m2/time,oral administration twice a day Day1-5,
TAS-102 oral administration twice a day Day8-12+Bevacizumab DIV5.0 mg/kg Day1,15
Primary outcome(s): Progression free survival
Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
DISEASE(S): Colorectal Cancer
PROVIDER: 2612965 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA